Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 3Completed 3Terminated 2Active not recruiting 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Solid Tumors 1Glioblastoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Cholangiocarcinoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1Adenocarcinoma of Lung 1

Interventions

Paclitaxel 9Carboplatin 8Bevacizumab 8fluzoparib 5olaparib 3Topotecan 3Gemcitabine 3liposomal doxorubicin 2famitinib 2apatinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Drug Therapy 2Cisplatin 2trametinib 1senaparib 1pembrolizumab 1niraparib 1montelukast 1irinotecan sucrosofate 1fludarabine 1durvalumab 1dalpiciclib 1dabrafenib 1ceralasertib 1anlotinib 1aldesleukin 1Ultrasonography, Doppler 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ovarian Neoplasms × Platinum × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡